Near-term
Platform
AI tools: digitised formulas, compound–target maps, docking and ADMET prediction.
For: Universities, CROs and research teams
The platform
A prototype research platform that traces Sowa Rigpa formulas to plants, compounds and biological targets, so the most promising leads can be tested in the lab.
Sowa-Omics™ is the research platform BBCRI is building. It brings together four things that are usually kept apart: the formulas of Sowa Rigpa, the medicinal plants of Bhutan, modern omics data, and artificial intelligence. The aim is to find promising therapeutic leads in traditional medicine and then test them properly.
Traditional knowledge points us to promising plants and formulas. Omics and computation tell us why they might work. The lab tells us whether they do.
Sowa Rigpa holds centuries of human-use experience with medicinal formulas, yet almost none of it has been mapped to molecular targets. That is an untapped discovery pipeline. BBCRI is building the proprietary data, AI and lab partnerships to turn it into licensable leads and products.
A traditional formula may contain many plants, and each plant contains many compounds. Working out which compounds matter, and what they act on in the body, is slow to do by hand. Computational tools can narrow thousands of possibilities to a short list worth testing in a laboratory.
Modern data layers: Genomics, Transcriptomics, Proteomics, Metabolomics, Systems biology, Bioinformatics, AI / ML, Phenotypic data.
Traditional knowledge layers: Medicinal plants, Traditional formulas, Bhutanese biodiversity.
Sowa-Omics™ is a working software prototype. The modules that trace an ingredient to its compounds and on to biological pathways run in an early web version. It is a prototype, not a finished product, and it has not yet produced a laboratory-validated lead. Building the curated database and the laboratory partnerships is the work of the next phases.
Near-term
AI tools: digitised formulas, compound–target maps, docking and ADMET prediction.
For: Universities, CROs and research teams
Near-term
Contract work in network pharmacology and in-silico screening, built on the same platform.
For: Institutions, agencies and companies
Mid-term
Standardised, scientifically validated formulations from Himalayan botanicals, sold under our own brand or licensed to partners.
For: Wellness brands and consumers
Long-term
Co-develop natural-product leads with industry partners through research fees, milestone payments and royalties.
For: Pharma and nutraceutical companies
No. It is a research tool. Nothing that comes out of it is called a therapy until it has been validated, and nothing on this site is medical advice.
No. Computation decides what is worth testing first. Whether a candidate works, and whether it is safe, can only be shown in the laboratory and, later, in clinical studies.
Built around Bhutan's access and benefit-sharing framework and the Nagoya Protocol, crediting knowledge holders. Lawful access is a barrier competitors cannot easily cross.
See our plain-language guide: AI drug discovery from medicinal plants.
We are opening conversations with research and industry partners now. See how to partner with us.
Investors, partners and customers: tell us what you have in mind. We reply to every message.